Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Foghorn Therapeutics (NASDAQ:FHTX) and lowers the price target from $13 to $10.
July 06, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Foghorn Therapeutics and lowered the price target from $13 to $10.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100